Danaher Stock Slump Seen as Potential Buying Opportunity Despite Earnings Report
Shares of Danaher have declined by over 12% this week following its second-quarter earnings report, despite beating estimates and raising full-year guidance. The stock's drop is attributed to a reduction in core sales growth expectations for the biotechnology segment, which has higher margins. Management cited delayed shipments from large commercial customers as the cause of weaker-than-expected performance. While Danaher raised its EPS outlook due partly to an earlier acquisition of Masimo, investors reacted negatively to the revised guidance and concerns over future profit margin impacts in high-margin areas like biotechnology. CEO Rainer Blair explained that some chromatography resin shipments were delayed beyond 2026 but emphasized shipment timing can be lumpy. Analysts suggest this sell-off may represent an overreaction rather than a fundamental issue, making the stock potentially attractive for long-term investors.
